Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety

被引:61
作者
Carboni, E
Wieland, S
Lan, NC
Gee, KW
机构
[1] UNIV CALIF IRVINE,COLL MED,DEPT PHARMACOL,IRVINE,CA 92717
[2] COCENSYS INC,DEPT PHARMACOL,IRVINE,CA 92718
关键词
gamma-aminobutyric acid; GABA(A) receptor complex; 3; alpha-hydroxy-5; alpha-pregnan-20-one; beta-pregnan-20-one; 5; alpha-pregnan-3; alpha; 20; alpha-diol; benzodiazepines; anxiolytic; neuroactive steroids; neurosteroids; Vogel test; elevated plus-maze; progesterone metabolites; benzodiazepine receptor;
D O I
10.1007/BF02246353
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Certain endogenously occurring 3 alpha-hydroxylated, 5-reduced pregnane steroids act at a specific site on the GABA(A) receptor complex (GRC) to modulate the effects of GABA at its receptor. Modulators that potentiate GABA at the GABA(A) receptor often possess anxiolytic properties. The anxiolytic potential of four 5-reduced, 3 alpha, 20-pregnanediols, differing only in the stereochemical orientation of the steroid A-ring and the 20-hydroxyl group, were tested in the Vogel test following intracerebroventricular (ICV) administration. The effects of these pregnanediols were compared to those of their 20-ketone analogues, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha,5 beta-P) and 3 alpha-hydroxy-5 beta-pregnan-20-one (3 alpha,5 beta-P). All four pregnanediols tested significantly enhanced punished drinking at doses ranging from 10 to 60 mu g. The rank order of potency based on the minimum effective dose (MED) observed was 5 alpha-pregnan-3 alpha,20 alpha-diol = 5 beta-pregnan-3 alpha,20 alpha-diol > 5 beta-pregnan-3 alpha,20 beta-diol > 5 alpha-pregnan-3 alpha,20 beta-diol. 3 alpha,5 beta-P and 3 alpha,5 alpha-P enhanced punished responding when administered at 2.5 and 5 mu g, respectively. 3 beta,5 alpha-P which is inactive at the GRC was also inactive (up to 100 mu g) in the Vogel test. The benzodiazepine control diazepam was efficacious when administered at 2.5 mu g. 5 alpha-Pregnan-3 alpha,20 alpha-diol was further tested in the mouse elevated plus-maze model following systemic administration where it was found to be active in a dose range of 10-40 mg/kg IP. These results raise the possibility that in addition to 3 alpha,5 alpha-P and 3 alpha,5 beta-P, some of their endogenously occurring pregnanediol metabolites may also influence physiological processes related to anxiety via the GRC.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 24 条
  • [1] [Anonymous], METABOLISM HORMONAL
  • [2] SEDATIVE AND HYPNOTIC EFFECTS OF ORAL-ADMINISTRATION OF MICRONIZED PROGESTERONE MAY BE MEDIATED THROUGH ITS METABOLITES
    ARAFAT, ES
    HARGROVE, JT
    MAXSON, WS
    DESIDERIO, DM
    WENTZ, AC
    ANDERSEN, RN
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 159 (05) : 1203 - 1209
  • [3] 5-ALPHA-PREGNAN-3-ALPHA,20-ALPHA-DIOL BEHAVES LIKE A PARTIAL AGONIST IN THE MODULATION OF GABA-STIMULATED CHLORIDE-ION UPTAKE BY SYNAPTONEUROSOMES
    BELELLI, D
    GEE, KW
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 167 (01) : 173 - 176
  • [4] ANXIOLYTIC EFFECT OF PROGESTERONE IS MEDIATED BY THE NEUROSTEROID ALLOPREGNANOLONE AT BRAIN GABA(A) RECEPTORS
    BITRAN, D
    SHIEKH, M
    MCLEOD, M
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 1995, 7 (03) : 171 - 177
  • [5] ANXIOLYTIC EFFECTS OF 3A-HYDROXY-5A[BETA]-PREGNAN-20-ONE - ENDOGENOUS METABOLITES OF PROGESTERONE THAT ARE ACTIVE AT THE GABA-A RECEPTOR
    BITRAN, D
    HILVERS, RJ
    KELLOGG, CK
    [J]. BRAIN RESEARCH, 1991, 561 (01) : 157 - 161
  • [6] NEUROSTEROIDS - 3-ALPHA-HYDROXY-5-ALPHA-PREGNAN-20-ONE AND ITS PRECURSORS IN THE BRAIN, PLASMA, AND STEROIDOGENIC GLANDS OF MALE AND FEMALE RATS
    CORPECHOT, C
    YOUNG, J
    CALVEL, M
    WEHREY, C
    VELTZ, JN
    TOUYER, G
    MOUREN, M
    PRASAD, VVK
    BANNER, C
    SJOVALL, J
    BAULIEU, EE
    ROBEL, P
    [J]. ENDOCRINOLOGY, 1993, 133 (03) : 1003 - 1009
  • [7] GEE KW, 1988, J PHARMACOL EXP THER, V246, P803
  • [8] GABA-DEPENDENT MODULATION OF THE CL- IONOPHORE BY STEROIDS IN RAT-BRAIN
    GEE, KW
    CHANG, WC
    BRINTON, RE
    MCEWEN, BS
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 136 (03) : 419 - 423
  • [9] GEE KW, 1995, CRIT REV NEUROBIOL, V9, P207
  • [10] HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346